SCYNEXIS, Inc. (SCYX)
5.15
-0.15
(-2.83%)
USD |
NASDAQ |
Sep 08, 16:00
SCYNEXIS Shareholders Equity (Quarterly) : 66.93M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 66.93M |
| March 31, 2026 | 41.31M |
| December 31, 2025 | 49.38M |
| September 30, 2025 | 36.43M |
| June 30, 2025 | 44.47M |
| March 31, 2025 | 50.53M |
| December 31, 2024 | 55.08M |
| September 30, 2024 | 58.53M |
| June 30, 2024 | 60.41M |
| March 31, 2024 | 74.10M |
| December 31, 2023 | 72.96M |
| September 30, 2023 | 91.99M |
| June 30, 2023 | 93.08M |
| March 31, 2023 | -29.91M |
| December 31, 2022 | 3.233M |
| September 30, 2022 | 17.21M |
| June 30, 2022 | 45.48M |
| March 31, 2022 | 38.93M |
| December 31, 2021 | 41.26M |
| September 30, 2021 | 37.61M |
| June 30, 2021 | 32.32M |
| March 31, 2021 | 25.92M |
| December 31, 2020 | 22.76M |
| September 30, 2020 | 9.558M |
| June 30, 2020 | 6.333M |
| Date | Value |
|---|---|
| March 31, 2020 | 6.455M |
| December 31, 2019 | 12.90M |
| September 30, 2019 | 6.143M |
| June 30, 2019 | 10.40M |
| March 31, 2019 | 11.33M |
| December 31, 2018 | 31.22M |
| September 30, 2018 | 27.88M |
| June 30, 2018 | 26.55M |
| March 31, 2018 | 36.84M |
| December 31, 2017 | 21.41M |
| September 30, 2017 | 27.26M |
| June 30, 2017 | 31.66M |
| March 31, 2017 | 33.53M |
| December 31, 2016 | 34.82M |
| September 30, 2016 | 33.18M |
| June 30, 2016 | 43.88M |
| March 31, 2016 | 35.04M |
| December 31, 2015 | 41.95M |
| September 30, 2015 | 49.97M |
| June 30, 2015 | 56.77M |
| March 31, 2015 | 27.44M |
| December 31, 2014 | 33.43M |
| September 30, 2014 | 36.14M |
| June 30, 2014 | 39.42M |
| March 31, 2014 | -20.42M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 597.21M |
| Corcept Therapeutics, Inc. | 705.78M |
| Veru, Inc. | 28.38M |
| Johnson & Johnson | 84.97B |
| Eli Lilly & Co. | 33.88B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 74.97M |
| Total Liabilities (Quarterly) | 8.04M |
| Debt to Equity Ratio | 0.0291 |
| Current Ratio | 9.563 |
| Net Debt Paydown Yield | 0.27% |